INOVIO is leveraging a cutting-edge platform to advance DNA medicine candidates with the potential to transform disease prevention and treatment paradigms and improve patients’ lives.
INO-3107: Potential Breakthrough Treatment for RRP in Adults
OVERVIEW
INO-3107 is a DNA immunotherapy that is designed to teach the body to mount an effective immune response to HPV-6 and HPV-11, the strains of HPV that cause Recurrent Respiratory Papillomatosis (RRP).
In a Phase 1/2 trial, 72% of patients saw a 50 to 100% reduction in the number of surgeries in the first year after starting treatment with INO-3107. INO-3107 was well tolerated, with most patients experiencing mostly low-grade (Grade 1) treatment-emergent AEs such as injection site pain and fatigue.
In a retrospective study involving 28 of the original trial participants (RRP-002), the number of patients experiencing a 50 to 100% reduction in surgeries increased to 86% in the second year, with no additional dosing. Half of those patients required no surgeries at all.
Published immunological data showed that INO-3107 induced new populations of antigen specific cytotoxic T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries.
